key: cord-0957473-mt9s6e20 authors: Lampejo, Temi title: The impact of the COVID‐19 pandemic on the global burden of influenza date: 2022-02-17 journal: J Med Virol DOI: 10.1002/jmv.27653 sha: d45799704998bc060e9c40b062ad40e67461cc27 doc_id: 957473 cord_uid: mt9s6e20 Annually, the World Health Organization (WHO) estimates that there are approximately 1 billion human influenza cases of which 3 to 5 million are considered severe (particularly in children, the elderly and in the immunocompromised) resulting in between 290,000 and 650,000 deaths This article is protected by copyright. All rights reserved. years (0.03% in 2020 vs. 3.6%-16.4% between 2012 and 2019). The fact that testing rates for influenza in the study region were higher in 2020 compared to previous years suggests that the lower influenza detection rates were not simply attributable to reduced healthseeking behavior and/or reduced testing (hypotheses for which the declines in influenza circulation were initially suggested by some 3, 9, 10 ). This study, however, did not include hospital admission data. It is important to note that unlike with COVID-19 where the disease burden in children appears to be relatively low compared to in adults, 11 influenza is responsible for significant morbidity in children (at times resulting in hospital admission rates on a par with the excess admission rates observed in at-risk adults 12 (before the COVID-19 pandemic declaration) suggesting that it could be a particularly severe influenza season. 13 The sudden fall in influenza activity in the Northern Hemisphere in the 2019-2020 influenza season occurred in early April 2020 just weeks after the declaration of the COVID-19 pandemic. 13 In Hong Kong, the 2019-2020 winter influenza season was 63.2% shorter compared to 2015-2019 and the number of deaths from laboratory-confirmed influenza in adults was 62.3% lower. 14 A study investigating the effect of enhanced public health intervention in China during the COVID-19 epidemic reported a 6.25% decrease in the positive influenza rate in 2020 compared to the previous 5 years. 15 In view of the ongoing COVID-19 pandemic, these observations continued in 2021 as demonstrated by a population-based Canadian study which found that during 2020-2021 influenza A and B rates decreased to 0.0015 and 0.0028 times that of prepandemic levels, respectively. 16 A finding which has been echoed in several other parts of the world. [17] [18] [19] The degree to which influenza vaccination rates played a role in defenses within the human respiratory epithelium. 28 The SARS-CoV-2-influenza viral interference hypothesis is, however, unsupported by the observed declines in influenza activity in the US even prior to widespread SARS-CoV-2 transmission across most of the country, 3 although lower SARS-CoV-2 testing rates at that early stage and/or a possible natural end to the 2019-2020 influenza season could have influenced these observations. Interestingly, PHE data (looking at 2019, 256 individuals who were tested for both SARS-CoV-2 and influenza between January 20 and April 25, 2020) found that the risk of testing positive for SARS-CoV-2 was 58% lower among influenzapositive cases. 29, 30 Data from New York (of 16 408 patients tested for SARS-CoV-2 between March 16 and April 20, 2020) revealed that the influenza infection rate was 0.08% in individuals in whom SARS-CoV-2 was detected compared to 1.54% (×19-fold greater) in individuals who tested negative for SARS-CoV-2. 31 Inferences with regard to viral interference between SARS-CoV-2 and influenza cannot be clearly made from these data. PHE data showed that the mortality was high at 43.1% in the 58 people with confirmed SARS-CoV-2-influenza coinfection; a mortality rate 2.72 times higher than in SARS-CoV-2 monoinfection (and 5.92 times higher than in individuals infected with neither virus) and therefore potentially synergistic effects between the two viruses has been suggested by the investigators 30 which is in stark contrast to SARS-CoV-2influenza viral interference hypothesis. It is unclear whether the particularly high mortality rate in coinfected individuals could possibly be attributed in part to behavioral changes amongst medical personnel in initiating anti-influenza treatment. In previous influenza seasons, many patients would be empirically prescribed a neuraminidase inhibitor when admitted to a healthcare facility with an influenza-like illness. In light of the COVID-19 pandemic, efforts have been primarily focused on initiating therapies for COVID-19 which could potentially lead to delays in starting anti-influenza treatment. The timing of treatment initiation for influenza is important given that most studies have suggested that oseltamivir is most effective when initiated within 48 h of illness onset. 32 However, if influenza activity remains at such low levels then this may be less of an issue than envisaged. There are valuable lessons and insights gained from the public health strategies (including mass vaccination) implemented during ongoing the COVID-19 pandemic, many of which may be important in reducing influenza-associated morbidity and mortality in the years ahead. The author declares no conflict of interest. Global Influenza Strategy 2019 to 2030. Weekly Epidemiology Monitor WHO Coronavirus (COVID-19) Dashboard. Accessed Decreased influenza activity during the COVID-19 pandemic-United States Collateral benefit of COVID-19 control measures on influenza activity Decreased influenza incidence under COVID-19 control measures Impact assessment of nonpharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an observational study Impact of public health interventions on seasonal influenza activity during the COVID-19 outbreak in Korea The impact of COVID-19 public health measures on detections of influenza and respiratory syncytial virus in children during the 2020 Australian winter The impact of COVID-19 pandemic on the health-seeking behaviour of an Asian population with acute respiratory infections in a densely populated community Double trouble? When a pandemic and seasonal virus collide COVID-19 infection in children Influenza related hospital admissions in children: evidence about the burden keeps growing but the route to policy change remains uncertain How coronavirus lockdowns stopped flu in its tracks Monitoring respiratory infections in covid-19 epidemics Effects of the enhanced public health intervention during the COVID-19 epidemic on respiratory and gastrointestinal infectious diseases in China The impact of the COVID-19 pandemic on influenza, respiratory syncytial virus, and other seasonal respiratory virus circulation in Canada: a populationbased study European Centre for Disease Prevention and Control. ECDC Seasonal influenza 2020−2021 Annual Epidemiological Report Influenza's unprecedented low profile during COVID-19 pandemic leaves experts wondering what this flu season has in store Centers for Disease Control and Prevention. CDC 2020-2021 Flu Season Summary. 2021. Accessed Intention of nurses to accept coronavirus disease 2019 vaccination and change of intention to accept seasonal influenza vaccination during the coronavirus disease 2019 pandemic: a cross-sectional survey Willingness of Hong Kong healthcare workers to accept pre-pandemic influenza vaccination at different WHO alert levels: two questionnaire surveys The impact of the COVID-19 pandemic on the uptake of influenza vaccine: UK-wide observational study Weekly National Influenza & COVID-19 Report: Week 44 Report National Foundation for Infectious Diseases. National Survey: Attitudes about Influenza, Pneumococcal Disease, and COVID-19 A case series of coinfection with SARS-CoV-2 and influenza virus in Louisiana Structural basis of receptor recognition by SARS-CoV-2 Interference between rhinovirus and influenza A virus: a clinical data analysis and experimental infection study Covid-19: risk of death more than doubled in people who also had flu, English data show Interactions between SARS-CoV-2 and influenza and the impact of coinfection on disease severity: a test negative design Coinfection in SARS-CoV-2 infected patients: where are influenza virus and rhinovirus/enterovirus? Impact of late oseltamivir treatment on influenza symptoms in the outpatient setting: results of a randomized trial